Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial
Introduction Greater understanding is required of how smokers with smokingrelated diseases respond to smoking cessation medications. This post hoc analysis of EAGLES data compared continuous abstinence rates (CARs) in smokers with/ without smoking-related diseases and assessed participant demograp...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Publishing
2022-05-01
|
| Series: | Tobacco Induced Diseases |
| Subjects: | |
| Online Access: | http://www.tobaccoinduceddiseases.org/Medication-assisted-quit-rates-in-participants-with-smoking-related-ndiseases-in,146567,0,2.html |
| _version_ | 1811240062289969152 |
|---|---|
| author | Philip Tønnesen David Lawrence Serena Tonstad |
| author_facet | Philip Tønnesen David Lawrence Serena Tonstad |
| author_sort | Philip Tønnesen |
| collection | DOAJ |
| description | Introduction
Greater understanding is required of how smokers with smokingrelated
diseases respond to smoking cessation medications. This post hoc analysis
of EAGLES data compared continuous abstinence rates (CARs) in smokers with/
without smoking-related diseases and assessed participant demographic and
baseline characteristics that may serve as predictors of continuous abstinence (CA).
Methods
EAGLES was a 24-week (12-week treatment, 12-week follow-up), doubleblind,
active- (nicotine replacement therapy; patch) and placebo-controlled study
in motivated-to-quit smokers with/without psychiatric disorders. This analysis
assessed CARs at weeks 9-12 (CAR9-12) and 9-24 (CAR9-24) in participants
with smoking-related diseases [asthma, chronic obstructive pulmonary disease
(COPD), diabetes, and/or cardiovascular disease (n=1372)] versus controls
without these comorbidities (n=6039). Participants received varenicline 1 mg
twice daily, bupropion 150 mg twice daily, nicotine patches 21 mg/day with taper,
or placebo for 12 weeks. Stepwise logistic modeling was also performed to analyze
odds ratio (OR) for predictors of CA at weeks 9-12 (CA9-12) and 9-24 (CA9-24).
Results
Smokers with smoking-related diseases were older, had a longer smoking
history, more quit attempts, and were more likely to have a psychiatric disorder
and reside in the US versus smokers without comorbidities. Fagerström Test for
Cigarette Dependence scores and treatment adherence were comparable between
cohorts. Smokers with smoking-related diseases had lower CARs versus controls
(CAR9-12: 20.8% vs 24.0%; CAR9-24: 13.0% vs 16.9%). Use of smoking cessation
medication was the strongest predictor of CA after control for demographics,
smoking characteristics, and psychiatric disorder. By treatment, OR and CI were:
varenicline CA9-12 (OR=3.82; 95% CI: 3.21-4.54) and CA9-24 (OR=2.92; 95%
CI: 2.40-3.54); bupropion CA9-12 (OR=2.17; 95% CI: 1.81-2.60) and CA9-24
(OR=1.99; 95% CI: 1.63-2.44); nicotine patches CA9-12 (OR=2.23; 95% CI:
1.87-2.67) and CA9-24 (OR=1.86; 95% CI: 1.52-2.28).
Conclusions
Smokers with smoking-related diseases had lower quit rates than
controls. Of the active treatments compared, varenicline was most effective in
smokers with asthma, COPD, diabetes, or cardiovascular disease. |
| first_indexed | 2024-04-12T13:12:41Z |
| format | Article |
| id | doaj.art-34f1def863ca42bd9e8d26b077653e13 |
| institution | Directory Open Access Journal |
| issn | 1617-9625 |
| language | English |
| last_indexed | 2024-04-12T13:12:41Z |
| publishDate | 2022-05-01 |
| publisher | European Publishing |
| record_format | Article |
| series | Tobacco Induced Diseases |
| spelling | doaj.art-34f1def863ca42bd9e8d26b077653e132022-12-22T03:31:48ZengEuropean PublishingTobacco Induced Diseases1617-96252022-05-0120May11110.18332/tid/146567146567Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trialPhilip Tønnesen0David Lawrence1https://orcid.org/0000-0001-8093-1013Serena Tonstad2Pulmonary Medicine, Søernes Privathospital, Frederiksberg, DenmarkGlobal Product Development, Pfizer Inc, New York, United StatesDepartment of Preventive Cardiology, Oslo University Hospital, Oslo, NorwayIntroduction Greater understanding is required of how smokers with smokingrelated diseases respond to smoking cessation medications. This post hoc analysis of EAGLES data compared continuous abstinence rates (CARs) in smokers with/ without smoking-related diseases and assessed participant demographic and baseline characteristics that may serve as predictors of continuous abstinence (CA). Methods EAGLES was a 24-week (12-week treatment, 12-week follow-up), doubleblind, active- (nicotine replacement therapy; patch) and placebo-controlled study in motivated-to-quit smokers with/without psychiatric disorders. This analysis assessed CARs at weeks 9-12 (CAR9-12) and 9-24 (CAR9-24) in participants with smoking-related diseases [asthma, chronic obstructive pulmonary disease (COPD), diabetes, and/or cardiovascular disease (n=1372)] versus controls without these comorbidities (n=6039). Participants received varenicline 1 mg twice daily, bupropion 150 mg twice daily, nicotine patches 21 mg/day with taper, or placebo for 12 weeks. Stepwise logistic modeling was also performed to analyze odds ratio (OR) for predictors of CA at weeks 9-12 (CA9-12) and 9-24 (CA9-24). Results Smokers with smoking-related diseases were older, had a longer smoking history, more quit attempts, and were more likely to have a psychiatric disorder and reside in the US versus smokers without comorbidities. Fagerström Test for Cigarette Dependence scores and treatment adherence were comparable between cohorts. Smokers with smoking-related diseases had lower CARs versus controls (CAR9-12: 20.8% vs 24.0%; CAR9-24: 13.0% vs 16.9%). Use of smoking cessation medication was the strongest predictor of CA after control for demographics, smoking characteristics, and psychiatric disorder. By treatment, OR and CI were: varenicline CA9-12 (OR=3.82; 95% CI: 3.21-4.54) and CA9-24 (OR=2.92; 95% CI: 2.40-3.54); bupropion CA9-12 (OR=2.17; 95% CI: 1.81-2.60) and CA9-24 (OR=1.99; 95% CI: 1.63-2.44); nicotine patches CA9-12 (OR=2.23; 95% CI: 1.87-2.67) and CA9-24 (OR=1.86; 95% CI: 1.52-2.28). Conclusions Smokers with smoking-related diseases had lower quit rates than controls. Of the active treatments compared, varenicline was most effective in smokers with asthma, COPD, diabetes, or cardiovascular disease.http://www.tobaccoinduceddiseases.org/Medication-assisted-quit-rates-in-participants-with-smoking-related-ndiseases-in,146567,0,2.htmlbupropionnicotine patchessmoking cessationsmoking-related diseasevarenicline |
| spellingShingle | Philip Tønnesen David Lawrence Serena Tonstad Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial Tobacco Induced Diseases bupropion nicotine patches smoking cessation smoking-related disease varenicline |
| title | Medication-assisted quit rates in participants with smoking-related
diseases in EAGLES: Post hoc analyses of a double-blind,
randomized, placebo-controlled clinical trial |
| title_full | Medication-assisted quit rates in participants with smoking-related
diseases in EAGLES: Post hoc analyses of a double-blind,
randomized, placebo-controlled clinical trial |
| title_fullStr | Medication-assisted quit rates in participants with smoking-related
diseases in EAGLES: Post hoc analyses of a double-blind,
randomized, placebo-controlled clinical trial |
| title_full_unstemmed | Medication-assisted quit rates in participants with smoking-related
diseases in EAGLES: Post hoc analyses of a double-blind,
randomized, placebo-controlled clinical trial |
| title_short | Medication-assisted quit rates in participants with smoking-related
diseases in EAGLES: Post hoc analyses of a double-blind,
randomized, placebo-controlled clinical trial |
| title_sort | medication assisted quit rates in participants with smoking related diseases in eagles post hoc analyses of a double blind randomized placebo controlled clinical trial |
| topic | bupropion nicotine patches smoking cessation smoking-related disease varenicline |
| url | http://www.tobaccoinduceddiseases.org/Medication-assisted-quit-rates-in-participants-with-smoking-related-ndiseases-in,146567,0,2.html |
| work_keys_str_mv | AT philiptønnesen medicationassistedquitratesinparticipantswithsmokingrelateddiseasesineaglesposthocanalysesofadoubleblindrandomizedplacebocontrolledclinicaltrial AT davidlawrence medicationassistedquitratesinparticipantswithsmokingrelateddiseasesineaglesposthocanalysesofadoubleblindrandomizedplacebocontrolledclinicaltrial AT serenatonstad medicationassistedquitratesinparticipantswithsmokingrelateddiseasesineaglesposthocanalysesofadoubleblindrandomizedplacebocontrolledclinicaltrial |